News | Peripheral Artery Disease (PAD) | May 17, 2017

Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System

System features distal embolic filter on peripheral angioplasty balloon to protect the lower limbs without additional devices or exchanges

Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System

May 17, 2017 — Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection (IEP). The company intends to launch the Vanguard IEP System in Europe to endovascular specialists performing lower limb angioplasty procedures.

The Vanguard IEP System represents the latest innovation of Contego's IEP technology, incorporating a peripheral angioplasty balloon and distal embolic filter on the same catheter. The system protects the lower limbs during angioplasty without the need for additional devices or exchanges. The Vanguard IEP System has an over-the-wire design with a sheathless integrated 150-micron pore filter distal to the angioplasty balloon. It is the first filter to feature in-vivo adjustability to suit varying vessel sizes and maximize capture efficiency.

"The Vanguard IEP System is an important step toward enhancing safety for patients undergoing peripheral angioplasty for occlusive disease," said Prof. Thomas Zeller, director of the Department of Angiology at Universitaets-Herzzentrum Freiburg in Bad Krozingen, Germany and principal investigator of the upcoming Vanguard clinical study. "This device will be of particular importance to patients at high risk for distal embolization, such as those with acute limb ischemia or chronic total occlusions, as well as those at higher risk should embolization occur, such as patients with critical limb ischemia and diabetes mellitus."

Contego has established a premier distribution network throughout Europe to sell the Vanguard IEP System. Their first IEP device, the Paladin Carotid Post-Dilation Balloon System was launched in Europe in 2016.

For more information: www.contegomedical.com

Related Content

Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
CMS considers eliminating cardiac bundled payments.
Feature | Business| August 16, 2017 | Dave Fornell
August 16, 2017 — The Centers for Medicare and Medicaid Services (CMS) announced a proposed rule to reduce the number
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Four Blue Cross Blue Shield Companies Issue Positive Medical Policies on HeartFlow FFRct Analysis
News | FFR Catheters| August 09, 2017
HeartFlow Inc. announced that four Blue Cross Blue Shield companies have each issued a positive medical policy for the...
Ra Medical Systems Granted Broad Patent for DABRA Catheter
News | Peripheral Artery Disease (PAD)| August 09, 2017
August 9, 2017 — Ra Medical Systems announced that the United States Patent and Trademark Office (USPTO) has granted
Roxwood Medical Announces Agreement With Abbott for U.S. Product Distribution
News | Catheters| August 09, 2017
Roxwood Medical Inc. recently announced it has entered into an exclusive agreement with Abbott for distribution of...
New Jersey Researcher Exploring New Stem Cell Therapies for Heart Attacks
News | Stem Cell Therapies| August 04, 2017
In petri dishes in her campus laboratory at New Jersey Institute of Technology, Alice Lee is developing colonies of...
Abbott Initiates XIENCE Short DAPT Clinical Trial
News | Antiplatelet and Anticoagulation Therapies| August 03, 2017
Abbott recently announced the first patient has been enrolled in a clinical study evaluating the short-term use of...
Overlay Init